p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Teratoid Tumor, AtypicalChoroid Plexus NeoplasmsAnaplastic AstrocytomaAnaplastic OligodendrogliomaBrainstem TumorsGiant Cell GlioblastomaGlioblastomaGliosarcomaMedulloblastomaNeuroectodermal Tumor, Primitive
Interventions
DRUG

azurin-derived cell-penetrating peptide p28

Given IV

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

20892

National Cancer Institute Pediatric Oncology Branch, Bethesda

27710

Duke University Medical Center, Durham

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60614

Lurie Children's Hospital-Chicago, Chicago

77030

Baylor College of Medicine, Houston

90027

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Pediatric Brain Tumor Consortium

NETWORK

NCT01975116 - p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | Biotech Hunter | Biotech Hunter